SVRA

Savara Inc.

Price Chart

Latest Quote

$5.50

+0.12 (+2.23%)

Current Price

Previous Close	$5.38
Open	$5.51
Day High	$5.62
Day Low	$5.38
Volume	3,574,329

Fetched: 2026-06-19T05:03:12

Stock Information

Shares Outstanding	204.93M
Total Debt	$30.11M
Cash Equivalents	$204.14M
Net Income	$-129.48M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.13B
EPS (TTM)	$-0.56
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.17B
Income	$-129.48M
Book/sh	$0.69
Cash/sh	$1.00
Employees	70

Financial Ratios

Quick Ratio	13.21
Current Ratio	13.47
Debt/Eq	17.11

Returns & Margins

ROA	-40.53%
ROE	-79.95%

Ownership

Insider Ownership	2.57%
Institutional Ownership	104.25%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-18.71
P/B	7.93

Analyst Data

Recommendation	strong_buy
Target Price	$10.94

Technical Indicators

SMA20	$5.19
SMA50	$5.26
SMA200	$5.08
RSI	62.30
ATR	0.2706

Shares Float	130.08M
Short Float	17.23%
Short Ratio	23.01
Volatility	0.27
Rel Volume	2.83

Performance History

Week	nan%
Month	nan%
Quarter	nan%
6 Months	nan%
YTD	nan%
Year	nan%
3 Years	nan%
5 Years	nan%
10 Years	nan%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$5.50	4,761,500
2026-06-17	$5.38	1,392,900
2026-06-16	$5.30	997,600
2026-06-15	$5.33	1,287,900
2026-06-12	$5.26	1,252,700
2026-06-11	$5.27	1,535,400
2026-06-10	$5.09	1,962,200
2026-06-09	$4.93	3,133,200
2026-06-08	$5.06	920,500
2026-06-05	$5.09	1,204,900
2026-06-04	$5.30	1,026,900
2026-06-03	$5.25	1,806,300
2026-06-02	$5.25	1,943,300
2026-06-01	$5.15	2,071,800
2026-05-29	$5.20	2,236,000
2026-05-28	$5.09	2,939,000
2026-05-27	$5.21	834,400
2026-05-26	$5.14	695,500
2026-05-22	$5.02	667,300
2026-05-21	$5.06	965,700
2026-05-20	$5.08	1,157,400
2026-05-19	$4.72	1,081,000

About Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

📰 Latest News

Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns

Simply Wall St. • 2026-06-08T17:13:34Z

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Motley Fool • 2026-05-23T22:33:51Z

Savara Inc. (SVRA) Reports Q1 Financial Results

Insider Monkey • 2026-05-22T18:43:22Z

US High Growth Tech Stocks To Watch

Simply Wall St. • 2026-04-27T17:38:27Z

Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim

Simply Wall St. • 2026-04-26T17:03:21Z

High Growth Tech Stocks To Watch In The US March 2026

Simply Wall St. • 2026-03-26T11:40:16Z

VR Adviser Adds Over 1 Million Savara Shares

Motley Fool • 2026-03-15T14:59:05Z

Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed

Simply Wall St. • 2026-03-06T10:12:17Z

Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears

MarketBeat • 2026-03-02T00:36:41Z

Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit

MarketBeat • 2026-02-15T16:03:09Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$122,763,000	$102,399,000	$59,210,000	$38,043,000
Other Income Expense	$-236,000	$51,000	$76,000	$-19,000
Net Non Operating Interest Income Expense	$4,162,000	$6,467,000	$4,436,000	$-88,000
Operating Expense	$122,763,000	$102,399,000	$59,210,000	$38,043,000
General And Administrative Expense	$42,056,000	$25,037,000	$15,668,000	$10,929,000
Total Other Finance Cost	-	-	$-4,436,000	$88,000
Interest Expense	-	-	-	$88,000
Interest Expense Non Operating	-	-	-	$88,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Net Interest Income	$4,162,000	$6,467,000	$4,436,000	$-88,000
Interest Income	$4,162,000	$6,467,000	$4,436,000	-
Normalized Income	$-118,601,000	$-95,932,000	$-54,774,000	$-38,131,000
Net Income From Continuing And Discontinued Operation	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Total Operating Income As Reported	$-123,547,000	$-103,196,000	$-60,007,000	$-38,839,000
Net Income Common Stockholders	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Net Income	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Net Income Including Noncontrolling Interests	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Net Income Continuous Operations	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Pretax Income	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Special Income Charges	$-546,000	$0	-	-
Interest Income Non Operating	$4,162,000	$6,467,000	$4,436,000	-
Operating Income	$-122,763,000	$-102,399,000	$-59,210,000	$-38,043,000
Depreciation Amortization Depletion Income Statement	$87,000	$130,000	$77,000	$31,000
Depreciation And Amortization In Income Statement	$87,000	$130,000	$77,000	$31,000
Per Share
Diluted EPS	$-0.53	$-0.48	$-0.33	$-0.25
Basic EPS	$-0.53	$-0.48	$-0.33	$-0.25
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-122,440,000	$-102,320,000	$-59,209,000	$-37,857,000
Total Unusual Items	$-236,000	$51,000	$76,000	$-19,000
Total Unusual Items Excluding Goodwill	$-236,000	$51,000	$76,000	$-19,000
Reconciled Depreciation	$87,000	$130,000	$77,000	$167,000
EBITDA (Bullshit earnings)	$-122,676,000	$-102,269,000	$-59,133,000	$-37,876,000
EBIT	$-122,763,000	$-102,399,000	$-59,210,000	$-38,043,000
Diluted Average Shares	$222,387,531	$198,191,936	$165,204,652	$152,771,817
Basic Average Shares	$222,387,531	$198,191,936	$165,204,652	$152,771,817
Diluted NI Availto Com Stockholders	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Other Special Charges	$546,000	-	-	-
Gain On Sale Of Security	$310,000	$51,000	$76,000	$-19,000
Other Taxes	$-784,000	$-797,000	$-797,000	$-796,000
Research And Development	$81,404,000	$78,029,000	$44,262,000	$27,879,000
Selling General And Administration	$42,056,000	$25,037,000	$15,668,000	$10,929,000
Other Gand A	$42,056,000	$25,037,000	$15,668,000	$10,929,000

Fetched: 2026-06-14

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$191,497,000	$161,112,000	$129,412,000	$97,122,000
Total Assets	$253,436,000	$212,879,000	$177,564,000	$139,777,000
Total Non Current Assets	$11,820,000	$10,744,000	$11,617,000	$10,823,000
Other Non Current Assets	$84,000	$242,000	$387,000	$116,000
Other Intangible Assets	$11,636,000	$10,337,000	$10,960,000	$10,656,000
Current Assets	$241,616,000	$202,135,000	$165,947,000	$128,954,000
Other Current Assets	$892,000	$455,000	$280,000	$71,000
Hedging Assets Current	$394,000	$0	-	-
Prepaid Assets	$3,374,000	$4,310,000	$2,343,000	$2,053,000
Receivables	$1,254,000	$1,043,000	$1,005,000	$954,000
Taxes Receivable	$1,254,000	$1,043,000	$1,005,000	$954,000
Cash Cash Equivalents And Short Term Investments	$235,702,000	$196,327,000	$162,319,000	$125,876,000
Cash And Cash Equivalents	$33,180,000	$15,128,000	$26,585,000	$52,100,000
Debt
Total Debt	$29,914,000	$26,735,000	$26,491,000	$26,142,000
Long Term Debt And Capital Lease Obligation	$29,907,000	$26,619,000	$26,348,000	$26,078,000
Long Term Debt	$29,907,000	$26,619,000	$26,348,000	$26,078,000
Current Debt And Capital Lease Obligation	$7,000	$116,000	$143,000	$64,000
Net Debt	-	$11,491,000	-	-
Current Debt	-	-	-	-
Other Current Borrowings	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$50,303,000	$41,430,000	$37,192,000	$31,999,000
Total Non Current Liabilities Net Minority Interest	$29,907,000	$26,706,000	$26,595,000	$26,132,000
Current Liabilities	$20,396,000	$14,724,000	$10,597,000	$5,867,000
Other Current Liabilities	$362,000	-	-	-
Payables And Accrued Expenses	$13,475,000	$9,591,000	$6,408,000	$3,438,000
Payables	$5,757,000	$4,545,000	$3,504,000	$1,334,000
Accounts Payable	$5,757,000	$4,545,000	$3,504,000	$1,334,000
Other Non Current Liabilities	-	$87,000	$247,000	$54,000
Equity
Common Stock Equity	$203,133,000	$171,449,000	$140,372,000	$107,778,000
Total Equity Gross Minority Interest	$203,133,000	$171,449,000	$140,372,000	$107,778,000
Stockholders Equity	$203,133,000	$171,449,000	$140,372,000	$107,778,000
Gains Losses Not Affecting Retained Earnings	$-87,000	$-750,000	$-271,000	$-605,000
Other Equity Adjustments	$-87,000	$-750,000	$-271,000	$-605,000
Retained Earnings	$-608,087,000	$-489,250,000	$-393,369,000	$-338,671,000
Other
Ordinary Shares Number	$204,567,283	$172,423,223	$138,143,545	$114,046,345
Share Issued	$204,567,283	$172,423,223	$138,143,545	$114,046,345
Tangible Book Value	$191,497,000	$161,112,000	$129,412,000	$97,122,000
Invested Capital	$233,040,000	$198,068,000	$166,720,000	$133,856,000
Working Capital	$221,220,000	$187,411,000	$155,350,000	$123,087,000
Capital Lease Obligations	$7,000	$116,000	$143,000	$64,000
Total Capitalization	$233,040,000	$198,068,000	$166,720,000	$133,856,000
Additional Paid In Capital	$811,103,000	$661,276,000	$533,872,000	$446,938,000
Capital Stock	$204,000	$173,000	$140,000	$116,000
Common Stock	$204,000	$173,000	$140,000	$116,000
Current Capital Lease Obligation	$7,000	$116,000	$143,000	$64,000
Pensionand Other Post Retirement Benefit Plans Current	$6,552,000	$5,017,000	$4,046,000	$2,365,000
Current Accrued Expenses	$7,718,000	$5,046,000	$2,904,000	$2,104,000
Net PPE	$100,000	$165,000	$270,000	$51,000
Accumulated Depreciation	$-2,333,000	$-2,162,000	$-2,012,000	$-1,923,000
Gross PPE	$2,433,000	$2,327,000	$2,282,000	$1,974,000
Leases	$333,000	$333,000	$333,000	$145,000
Other Properties	$1,980,000	$1,874,000	$1,839,000	$1,768,000
Machinery Furniture Equipment	$120,000	$120,000	$110,000	$61,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$202,522,000	$181,199,000	$135,734,000	$73,776,000

Fetched: 2026-06-14

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-101,059,000	$-89,113,000	$-51,357,000	$-34,563,000
Operating Activities
Operating Cash Flow	$-101,037,000	$-89,088,000	$-51,061,000	$-34,554,000
Cash Flow From Continuing Operating Activities	$-101,037,000	$-89,088,000	$-51,061,000	$-34,554,000
Operating Gains Losses	$704,000	$145,000	$22,000	$19,000
Investing Activities
Capital Expenditure	$-22,000	$-25,000	$-296,000	$-9,000
Investing Cash Flow	$-18,440,000	$-39,941,000	$-57,116,000	$52,645,000
Cash Flow From Continuing Investing Activities	$-18,440,000	$-39,941,000	$-57,116,000	$52,645,000
Financing Activities
Repurchase Of Capital Stock	$-5,140,000	$-995,000	$-1,208,000	$-3,000
Issuance Of Capital Stock	$140,228,000	$118,172,000	$83,705,000	$0
Financing Cash Flow	$137,806,000	$117,577,000	$82,780,000	$87,000
Cash Flow From Continuing Financing Activities	$137,806,000	$117,577,000	$82,780,000	$87,000
Net Common Stock Issuance	$135,088,000	$117,177,000	$82,497,000	$-3,000
Common Stock Issuance	$140,228,000	$118,172,000	$83,705,000	$0
Net Other Financing Charges	-	$46,000	-	-
Other
Repayment Of Debt	$-27,229,000	$0	$0	$-26,350,000
Issuance Of Debt	$29,598,000	$0	$0	$26,438,000
Interest Paid Supplemental Data	$3,201,000	$2,124,000	$2,040,000	$1,614,000
End Cash Position	$33,180,000	$15,128,000	$26,585,000	$52,100,000
Beginning Cash Position	$15,128,000	$26,585,000	$52,100,000	$34,012,000
Effect Of Exchange Rate Changes	$-277,000	$-5,000	$-118,000	$-90,000
Changes In Cash	$18,329,000	$-11,452,000	$-25,397,000	$18,178,000
Proceeds From Stock Option Exercised	$349,000	$354,000	$283,000	$2,000
Common Stock Payments	$-5,140,000	$-995,000	$-1,208,000	$-3,000
Net Issuance Payments Of Debt	$2,369,000	$0	$0	$88,000
Net Long Term Debt Issuance	$2,369,000	$0	$0	$88,000
Long Term Debt Payments	$-27,229,000	$0	$0	$-26,350,000
Long Term Debt Issuance	$29,598,000	$0	$0	$26,438,000
Net Investment Purchase And Sale	$-18,418,000	$-39,916,000	$-56,820,000	$52,654,000
Sale Of Investment	$186,481,000	$165,000,000	$137,400,000	$142,069,000
Purchase Of Investment	$-204,899,000	$-204,916,000	$-194,220,000	$-89,415,000
Net PPE Purchase And Sale	$-22,000	$-25,000	$-296,000	$-9,000
Purchase Of PPE	$-22,000	$-25,000	$-296,000	$-9,000
Change In Working Capital	$5,001,000	$1,829,000	$4,073,000	$960,000
Change In Other Current Assets	$98,000	$11,000	$-12,000	$-57,000
Change In Payables And Accrued Expense	$4,806,000	$4,201,000	$4,541,000	$-319,000
Change In Payable	$4,806,000	$4,201,000	$4,541,000	$-319,000
Change In Account Payable	$4,806,000	$4,201,000	$4,541,000	$-319,000
Change In Prepaid Assets	$97,000	$-2,383,000	$-456,000	$1,336,000
Other Non Cash Items	$453,000	$271,000	$271,000	$334,000
Stock Based Compensation	$14,421,000	$9,860,000	$4,178,000	$2,041,000
Amortization Of Securities	$-2,866,000	$-5,442,000	$-4,984,000	$75,000
Depreciation Amortization Depletion	$87,000	$130,000	$77,000	$167,000
Depreciation And Amortization	$87,000	$130,000	$77,000	$167,000
Gain Loss On Sale Of PPE	$158,000	$145,000	$98,000	-
Net Income From Continuing Operations	$-118,837,000	$-95,881,000	$-54,698,000	$-38,150,000
Net Foreign Currency Exchange Gain Loss	-	$0	$-76,000	$19,000
Depreciation	-	-	$175,000	$167,000
Change In Other Current Liabilities	-	-	-	$0
Net Intangibles Purchase And Sale	-	-	-	-
Purchase Of Intangibles	-	-	-	-
Unrealized Gain Loss On Investment Securities	-	-	-	-

Fetched: 2026-06-14